Zuprevo
Active substance
ATC code
Species
Cattle
Indications
For the treatment and prevention of bovine respiratory disease (BRD) associated with Histophilus somni, Mannheimia haemolytica and Pasteurella multocida.
The presence of the disease in the group must be established before the product is used.
Dose to be administered and administration route
Subcutaneous use.
Administer 4 mg tildipirosin/kg body weight (equivalent to 1 ml/45 kg body weight) once only. For treatment of cattle over 450 kg body weight, divide the dose so that no more than 10 ml are injected at one site.
The rubber stopper of the vial may be safely punctured up to 20 times. Otherwise, the use of a multiple-dose syringe is recommended.
To ensure a correct dosage, bodyweight should be determined as accurately as possible.
It is recommended to treat animals in the early stages of the disease and to evaluate the response to treatment within 2 to 3 days after injection. If clinical signs of respiratory disease persist or increase, treatment should be changed using another antibiotic, and continued until clinical signs have resolved.
Adverse reactions
Cattle
|
Very common (>1 animal / 10 animals treated): |
Immediate pain upon injection, Injection site swelling1, Injection site pain2, Injection site reaction3 |
|
Very rare (<1 animal / 10,000 animals treated, including isolated reports): |
Anaphylaxis4 |
1 may be present up to 21 days post treatment
2 may be present up to 1 day post treatment
3 pathomorphological, will largely resolve within 35 days
4 may be fatal
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See the package leaflet for respective contact details.
TRUSTED SOURCE
